N/A
Completed N=127
Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)
Source: ClinicalTrials.gov NCT04428502 ↗Enrolled (actual)
127
Serious AEs
—
Results posted
Sep 2021
Primary outcomePrimary: Change From Baseline in Disease Activity in Psoriatic Arthritis (DAPSA) Score at Month 1
Summary
This study is to evaluate the local data in Iraqi patients with psoriatic arthritis on Enbrel treatment with positive Anti-Cyclic Citrullinated Peptide using data from the Rheumatologist in Baghdad Teaching Hospital registry.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Disease Activity in Psoriatic Arthritis (DAPSA) Score at Month 1 |
— | — |
| PRIMARY Change From Baseline in Disease Activity in Psoriatic Arthritis (DAPSA) Score at Month 12 |
— | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosed PsA patients.
- ≥18 years of age
- Have not received previous biological treatment
Exclusion Criteria
- Previous use of other biological treatments.
- Etanercept use for less than 1 year duration.
Data sourced from ClinicalTrials.gov (NCT04428502). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.